prikaz prve stranice dokumenta Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis
  Preuzmi
PDF 219.47 KB
Znanstveni rad - Izvorni znanstveni rad
Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis
Internal Medicine, 50 (2011), 9; 1009-1013. https://doi.org/10.2169/internalmedicine.50.4270
Duraković, Nadira; Radojčić, Vedran; Boban, Ana; Mrsić, Mirando; Sertić, Dubravka; Serventi-Seiwerth, Ranka; Nemet, Damir; Labar, Boris

Institucijski repozitorij: Dr Med - digitalni repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu

Citirajte ovaj rad

Duraković, N., Radojčić, V., Boban, A., Mrsić, M., Sertić, D., Serventi Seiwerth, R. ... Labar, B. (2011). Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis. Internal Medicine, 50. (9), 1009-1013. doi: 10.2169/internalmedicine.50.4270

Duraković, Nadira, et al. "Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis." Internal Medicine, vol. 50, br. 9, 2011, str. 1009-1013. https://doi.org/10.2169/internalmedicine.50.4270

Duraković, Nadira, Vedran Radojčić, Ana Boban, Mirando Mrsić, Dubravka Sertić, Ranka Serventi Seiwerth, Damir Nemet i Boris Labar. "Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis." Internal Medicine 50, br. 9 (2011): 1009-1013. https://doi.org/10.2169/internalmedicine.50.4270

Duraković, N., et al. (2011) 'Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis', Internal Medicine, 50(9), str. 1009-1013. doi: 10.2169/internalmedicine.50.4270

Duraković N, Radojčić V, Boban A, Mrsić M, Sertić D, Serventi Seiwerth R, i sur.. Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis. Internal Medicine [Internet]. 2011. [pristupljeno 11.05.2024.];50(9):1009-1013. doi: 10.2169/internalmedicine.50.4270

N. Duraković, et al., "Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis", Internal Medicine, vol. 50, br. 9, str. 1009-1013, 2011. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:311976. [Citirano: 11.05.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:311976
Podaci o radu
Naslov (engleski)Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis
AutorNadira Duraković
AutorVedran Radojčić
AutorAna Boban
AutorMirando Mrsić
AutorDubravka Sertić
AutorRanka Serventi-Seiwerth
AutorDamir Nemet
AutorBoris Labar
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
OBJECTIVE: A rise in infections with multidrug-resistant Pseudomonas aeruginosa (MDR-PA) is a significant contributor to increased morbidity and mortality of patients with hematologic malignancies. The aim of this study was to determine the efficacy and safety of colistin (colistimethate sodium) in the treatment of serious infections caused by MDR-PA in these patients. ----- PATIENTS AND METHODS: A matched pair analysis of renal function, toxicities, and outcome of 26 patients receiving colistin and control subjects was done. All patients had clinical signs of sepsis; P. aeruginosa was isolated from blood in 69% of patients in colistin group and 84% in control group. Patients treated with colistin received 3 million units every 8 hours for a median duration of 13 days. Additionally, patients received at least two additional antimicrobial or antifungal drugs. ----- RESULTS: Resolution of infection was achieved in twenty patients (76.9%) receiving colistin and in 17 (65.4%) control subjects. Mortality rate was 11% in both groups. There was no statistically significant difference in the level of serum creatinine, creatinine clearance, or potassium levels before and after treatment between groups. Only one patient receiving colistin developed de novo renal failure and one displayed transient neurologic toxicity. ----- CONCLUSION: Our results suggest that in patients with hematologic malignancies, colistin is effective in treating severe infections caused by MDR-PA while maintaining an acceptable toxicity profile. Prospective randomized studies comparing efficacy and safety of colistin with those of other antipseudomonal drugs are needed.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaInternal Medicine
Brojčani podacivol. 50, br. 9, str. 1009-1013
p-ISSN0918-2918
DOIhttps://doi.org/10.2169/internalmedicine.50.4270
URN:NBNurn:nbn:hr:105:311976
Datum objave publikacije2011
URL dokumentahttps://doi.org/10.2169/internalmedicine.50.4270
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-03-27 19:03:52